Silence Therapeutics plc (NASDAQ:SLN) Receives Consensus Rating of “Buy” from Analysts

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been assigned an average recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have covered the stock in the last year is $57.20.

SLN has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Monday, December 9th. Jefferies Financial Group assumed coverage on Silence Therapeutics in a research report on Tuesday, September 3rd. They set a “buy” rating and a $40.00 target price on the stock. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Chardan Capital reissued a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $49.00 target price on shares of Silence Therapeutics in a report on Tuesday, October 8th.

Silence Therapeutics Stock Performance

Shares of SLN stock opened at $6.45 on Friday. The firm’s 50 day moving average price is $13.69 and its 200-day moving average price is $17.14. Silence Therapeutics has a one year low of $5.81 and a one year high of $27.72. The firm has a market cap of $193.04 million, a P/E ratio of -4.11 and a beta of 1.05.

Institutional Trading of Silence Therapeutics

Institutional investors have recently modified their holdings of the company. Values First Advisors Inc. acquired a new position in Silence Therapeutics during the 3rd quarter worth $56,000. Quarry LP acquired a new position in shares of Silence Therapeutics during the 2nd quarter worth approximately $114,000. Verition Fund Management LLC bought a new stake in Silence Therapeutics in the 3rd quarter valued at $207,000. Custom Index Systems LLC acquired a new position in Silence Therapeutics in the second quarter valued at about $282,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Silence Therapeutics during the 3rd quarter worth $318,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.